Tag Archives: Research and Development

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Research: Working Together Toward Cures

Jim Greenwood

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require robust collaboration and coordination among industry, research institutions and physicians. By bringing together the brightest minds in medical research, our nation’s research enterprise has successfully brought hundreds of new drugs, biologics, and vaccines to market in recent years and developed a wealth of clinical prescribing information. Ongoing research is advancing the fight against some of humanity’s worst scourges, such as Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

Ernst & Young

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum. The Super Session at the 2012 BIO International Convention was moderated by members of Ernst & Young’s life sciences leadership team: Glen Giovannetti, Gautam Jaggi and Sanjeev Wadhwa; Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,